Cargando…

A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer

The biomarkers for the pathological response of neoadjuvant chemotherapy plus anti-programmed cell death protein-1/programmed cell death-ligand 1 (PD-1/PD-L1) (CAPD) are unclear in non-small cell lung cancer (NSCLC). Two hundred and eleven patients with stage Ib-IIIa NSCLC undergoing CAPD prior to s...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jie, Zou, Dan, Han, Lijie, Yin, Zuomin, Hu, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797141/
https://www.ncbi.nlm.nih.gov/pubmed/35095850
http://dx.doi.org/10.3389/fimmu.2021.778276
_version_ 1784641480224145408
author Peng, Jie
Zou, Dan
Han, Lijie
Yin, Zuomin
Hu, Xiao
author_facet Peng, Jie
Zou, Dan
Han, Lijie
Yin, Zuomin
Hu, Xiao
author_sort Peng, Jie
collection PubMed
description The biomarkers for the pathological response of neoadjuvant chemotherapy plus anti-programmed cell death protein-1/programmed cell death-ligand 1 (PD-1/PD-L1) (CAPD) are unclear in non-small cell lung cancer (NSCLC). Two hundred and eleven patients with stage Ib-IIIa NSCLC undergoing CAPD prior to surgical resection were enrolled, and 11 immune cell subsets in peripheral blood were prospectively analyzed using multicolor flow cytometry. Immune cell subtypes were selected by recursive feature elimination and least absolute shrinkage and selection operator methods. The support vector machine (SVM) was used to build a model. Multivariate analysis for major pathological response (MPR) was also performed. Finally, five immune cell subtypes were identified and an SVM based on liquid immune profiling (LIP-SVM) was developed. The LIP-SVM model achieved high accuracies in discovery and validation sets (AUC = 0.886, 95% CI: 0.823–0.949, P < 0.001; AUC = 0.874, 95% CI: 0.791–0.958, P < 0.001, respectively). Multivariate analysis revealed that age, radiological response, and LIP-SVM were independent factors for MPR in the two sets (each P < 0.05). The integration of LIP-SVM, clinical factors, and radiological response showed significantly high accuracies for predicting MPR in discovery and validation sets (AUC = 0.951, 95% CI: 0.916–0.986, P < 0.001; AUC = 0.943, 95% CI: 0.912–0.993, P < 0.001, respectively). Based on immune cell profiling of peripheral blood, our study developed a predictive model for the MPR of patients with NSCLC undergoing CAPD treatment that can potentially guide clinical therapy.
format Online
Article
Text
id pubmed-8797141
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87971412022-01-29 A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer Peng, Jie Zou, Dan Han, Lijie Yin, Zuomin Hu, Xiao Front Immunol Immunology The biomarkers for the pathological response of neoadjuvant chemotherapy plus anti-programmed cell death protein-1/programmed cell death-ligand 1 (PD-1/PD-L1) (CAPD) are unclear in non-small cell lung cancer (NSCLC). Two hundred and eleven patients with stage Ib-IIIa NSCLC undergoing CAPD prior to surgical resection were enrolled, and 11 immune cell subsets in peripheral blood were prospectively analyzed using multicolor flow cytometry. Immune cell subtypes were selected by recursive feature elimination and least absolute shrinkage and selection operator methods. The support vector machine (SVM) was used to build a model. Multivariate analysis for major pathological response (MPR) was also performed. Finally, five immune cell subtypes were identified and an SVM based on liquid immune profiling (LIP-SVM) was developed. The LIP-SVM model achieved high accuracies in discovery and validation sets (AUC = 0.886, 95% CI: 0.823–0.949, P < 0.001; AUC = 0.874, 95% CI: 0.791–0.958, P < 0.001, respectively). Multivariate analysis revealed that age, radiological response, and LIP-SVM were independent factors for MPR in the two sets (each P < 0.05). The integration of LIP-SVM, clinical factors, and radiological response showed significantly high accuracies for predicting MPR in discovery and validation sets (AUC = 0.951, 95% CI: 0.916–0.986, P < 0.001; AUC = 0.943, 95% CI: 0.912–0.993, P < 0.001, respectively). Based on immune cell profiling of peripheral blood, our study developed a predictive model for the MPR of patients with NSCLC undergoing CAPD treatment that can potentially guide clinical therapy. Frontiers Media S.A. 2021-12-15 /pmc/articles/PMC8797141/ /pubmed/35095850 http://dx.doi.org/10.3389/fimmu.2021.778276 Text en Copyright © 2021 Peng, Zou, Han, Yin and Hu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Peng, Jie
Zou, Dan
Han, Lijie
Yin, Zuomin
Hu, Xiao
A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer
title A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer
title_full A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer
title_fullStr A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer
title_full_unstemmed A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer
title_short A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer
title_sort support vector machine based on liquid immune profiling predicts major pathological response to chemotherapy plus anti-pd-1/pd-l1 as a neoadjuvant treatment for patients with resectable non-small cell lung cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797141/
https://www.ncbi.nlm.nih.gov/pubmed/35095850
http://dx.doi.org/10.3389/fimmu.2021.778276
work_keys_str_mv AT pengjie asupportvectormachinebasedonliquidimmuneprofilingpredictsmajorpathologicalresponsetochemotherapyplusantipd1pdl1asaneoadjuvanttreatmentforpatientswithresectablenonsmallcelllungcancer
AT zoudan asupportvectormachinebasedonliquidimmuneprofilingpredictsmajorpathologicalresponsetochemotherapyplusantipd1pdl1asaneoadjuvanttreatmentforpatientswithresectablenonsmallcelllungcancer
AT hanlijie asupportvectormachinebasedonliquidimmuneprofilingpredictsmajorpathologicalresponsetochemotherapyplusantipd1pdl1asaneoadjuvanttreatmentforpatientswithresectablenonsmallcelllungcancer
AT yinzuomin asupportvectormachinebasedonliquidimmuneprofilingpredictsmajorpathologicalresponsetochemotherapyplusantipd1pdl1asaneoadjuvanttreatmentforpatientswithresectablenonsmallcelllungcancer
AT huxiao asupportvectormachinebasedonliquidimmuneprofilingpredictsmajorpathologicalresponsetochemotherapyplusantipd1pdl1asaneoadjuvanttreatmentforpatientswithresectablenonsmallcelllungcancer
AT pengjie supportvectormachinebasedonliquidimmuneprofilingpredictsmajorpathologicalresponsetochemotherapyplusantipd1pdl1asaneoadjuvanttreatmentforpatientswithresectablenonsmallcelllungcancer
AT zoudan supportvectormachinebasedonliquidimmuneprofilingpredictsmajorpathologicalresponsetochemotherapyplusantipd1pdl1asaneoadjuvanttreatmentforpatientswithresectablenonsmallcelllungcancer
AT hanlijie supportvectormachinebasedonliquidimmuneprofilingpredictsmajorpathologicalresponsetochemotherapyplusantipd1pdl1asaneoadjuvanttreatmentforpatientswithresectablenonsmallcelllungcancer
AT yinzuomin supportvectormachinebasedonliquidimmuneprofilingpredictsmajorpathologicalresponsetochemotherapyplusantipd1pdl1asaneoadjuvanttreatmentforpatientswithresectablenonsmallcelllungcancer
AT huxiao supportvectormachinebasedonliquidimmuneprofilingpredictsmajorpathologicalresponsetochemotherapyplusantipd1pdl1asaneoadjuvanttreatmentforpatientswithresectablenonsmallcelllungcancer